Development
Moderna, Inc.
MRNA
$25.35
-$1.77-6.53%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -85.19% | -448.03% | -162.81% | -97.84% | -69.91% |
| Total Depreciation and Amortization | 152.50% | 120.35% | 21.05% | -1.27% | 2.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.78% | -- | -30.52% | -183.33% | 78.95% |
| Change in Net Operating Assets | 62.75% | 120.13% | 131.63% | -28.68% | 110.44% |
| Cash from Operations | -62.58% | -734.92% | -400.99% | -144.34% | -49.79% |
| Capital Expenditure | -139.13% | -57.30% | -168.97% | 14.39% | 23.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.74% | -10.15% | 304.51% | 158.30% | 6.09% |
| Cash from Investing | 48.66% | -16.51% | 268.75% | 151.29% | 7.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -103.28% | -41.30% | -21.74% | 19.35% | -38.64% |
| Issuance of Common Stock | -40.00% | -36.36% | -5.88% | -25.00% | -10.71% |
| Repurchase of Common Stock | 100.00% | -- | 51.62% | 15.57% | 53.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 75.11% | 94.43% | 49.66% | 15.58% | 49.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -114.20% | -657.05% | 116.60% | 113.56% | -86.45% |